SAGE News and Press, Sage Therapeutics Inc. From 12/08/21

Patients receiving zuranolone 50 mg in the WATERFALL Study demonstrated rapid improvements in depressive and anxiety symptoms, as early as the first measured timepoint (Day 3 for HAMD-17 and Day 8 for HAM-A), with average improvements maintained through the end of the study (Day 42) ...

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total Zuranolone 50 mg was generally well-tolerated w...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Piper San...

Praxis is developing a potential first-in-class drug candidate, PRAX-114, in major depressive disorder. With clinical catalysts coming up in early 2022 for PRAX-114, there is a window of opportunity to invest in the company. Praxis also has a unique rare-to-common drug discovery p...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Stifel 20...

The following slide deck was published by Sage Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Sage Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation

SAGE Therapeutics, Inc. (SAGE) Q3 2021 Results Earnings Conference Call November 2, 2021, 08:00 AM ET Company Participants Helen Rubenstein - Investor Contact Barry Greene - Chief Executive Officer Steve Kanes - Chief Medical Officer Jim Doherty - Chief Research Officer Kimi Iguchi - Chief Fi...

Image source: The Motley Fool. Sage Therapeutics Inc (NASDAQ: SAGE) Q3 2021 Earnings Call Nov 2, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Sage Therapeutics Inc (SAGE) Q3 2021 Earnings Call Transcript

Sage Therapeutics (SAGE -5.7%) has approached a 52-week low after the company announced the resignation of its chief medical officer today with its Q3 2021 earnings release that also fell short of expectations. Steve Kanes is leaving the company to take over the CEO role of a private bio...

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global...